悦康药业2025年净亏损2.54亿元

Core Viewpoint - Yuyuan Pharmaceutical reported a significant decline in revenue and net loss for the year 2025, indicating challenges in its business performance and strategic adjustments in product pricing and sales [1] Financial Performance - The company achieved total operating revenue of 2.446 billion yuan in 2025, a year-on-year decrease of 35.3% [1] - The net loss attributable to the parent company was 254 million yuan, representing a year-on-year increase of 305.18% [1] - The net loss attributable to the parent company, excluding non-recurring gains and losses, was 280 million yuan, reflecting a year-on-year increase of 352.83% [1] Strategic Adjustments - At the end of 2024, the company adjusted the pricing and sales strategy for its product "Ginkgo Biloba Extract Injection," which had a significant impact on revenue and profit [1] - The increase in research and development expenses during the reporting period also contributed to the negative impact on net profit [1]